Jupiter Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jupiter Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$657K	Buy	+11,479	New	+$629K	﹤0.01%	459
2021 Q4	–	Sell	-23,471	Closed	-$1.81M	–	558
2021 Q3	$1.81M	Buy	23,471 +13,598	+138%	+$1.07M	0.02%	353
2021 Q2	$824K	Buy	+9,873	New	+$783K	0.01%	454
2021 Q1	–	Sell	-5,416	Closed	-$474K	–	573
2020 Q4	$474K	Buy	+5,416	New	+$429K	﹤0.01%	513

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jupiter Asset Management's BMRN Position: Q2 2026 in Review

Jupiter Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 11,479 shares worth $657K. The stake represents ﹤0.01% of the portfolio and ranks #459 among its holdings. This is a return to the name: Jupiter Asset Management previously reported a position in BMRN as recently as Q3 2021.

Jupiter Asset Management first reported a position in BMRN in Q4 2020 and has held it in 4 quarters since. The position peaked at $1.81M in Q3 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Jupiter Asset Management held 11,479 shares of BioMarin Pharmaceuticals worth $657K as of Q2 2026.
BioMarin Pharmaceuticals was a new Jupiter Asset Management position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Jupiter Asset Management's portfolio in Q2 2026, its #459 holding.
Jupiter Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 4 quarters since.
Jupiter Asset Management's BioMarin Pharmaceuticals position peaked at $1.81M in Q3 2021.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.